Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

被引：0
|
作者：
Cerrato, Clara [1 ]
Pradere, Benjamin [2 ]
Mir, Maria Carmen [3 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Southampton, England
[2] La Croix Du Sud Hosp, Dept Urol, Quint Fonsegrives, France
[3] Univ Hosp Ribera, Dept Urol, Valencia, Spain
来源：
EUROPEAN UROLOGY | 2023年 / 84卷 / 04期
关键词：
D O I：
10.1016/j.eururo.2023.06.027
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E93 / E93
页数：1
相关论文
共 50 条
  • [1] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [2] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [3] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [4] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [5] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. Aren
    Melichar, B.
    Choueiri, T. K.
    Plimack, Elizabeth R.
    Barthelemy, P.
    Porta, C.
    George, S.
    Powles, T.
    Donskov, F.
    Neiman, V.
    Kollmannsberger, C. K.
    Salman, P.
    Gurney, H.
    Hawkins, R.
    Ravaud, A.
    Grimm, M. -O.
    Bracarda, S.
    Barrios, C. H.
    Tomita, Y.
    Castellano, D.
    Rini, B. I.
    Chen, A. C.
    Mekan, S.
    McHenry, M. B.
    Wind-Rotolo, M.
    Doan, J.
    Sharma, P.
    Hammers, H. J.
    Escudier, B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14): : 1277 - 1290
  • [6] Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
    不详
    [J]. EUROPEAN UROLOGY, 2021, 80 (02) : 256 - 257
  • [7] Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma
    Powles, Tom
    [J]. EUROPEAN UROLOGY, 2018, 74 (05) : 679 - 680
  • [8] ECONOMIC EVALUATION OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED RENAL-CELL CARCINOMA IN JAPAN
    Maeda, T.
    Morimoto, K.
    Mo, X.
    Moriwaki, K.
    Shimozuma, K.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S188 - S189
  • [9] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    [J]. FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [10] Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.
    Gedye, Craig
    Pook, David William
    Krieger, Laurence Eliot Miles
    Harris, Carole A.
    Goh, Jeffrey C.
    Kichenadasse, Ganessan
    Gurney, Howard
    Underhill, Craig
    Parnis, Francis
    Joshua, Anthony M.
    Ferguson, Tom
    Roncolato, Felicia
    Harrison, Michelle L.
    Begbie, Stephen
    Morris, Michelle Frances
    Hovey, Elizabeth J.
    George, Mathew
    Prithviraj, Prashanth
    Link, Emma
    Davis, Ian D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345